Janssen Announces Respiratory Syncytial Virus (RSV) Adult Vaccine Candidate Maintains Significant Efficacy Regardless of Lower Respiratory Tract Disease Severity
- EMEA Innovative Medicine
- Janssen Announces Respiratory Syncytial Virus (RSV) Adult Vaccine Candidate Maintains Significant Efficacy Regardless of Lower Respiratory Tract Disease Severity
Janssen Announces Respiratory Syncytial Virus (RSV) Adult Vaccine Candidate Maintains Significant Efficacy Regardless of Lower Respiratory Tract Disease Severity
- X (Twitter)
Copy link